[go: up one dir, main page]

AU2273701A - Hla class i a2 tumor associated antigen peptides and vaccine compositions - Google Patents

Hla class i a2 tumor associated antigen peptides and vaccine compositions

Info

Publication number
AU2273701A
AU2273701A AU22737/01A AU2273701A AU2273701A AU 2273701 A AU2273701 A AU 2273701A AU 22737/01 A AU22737/01 A AU 22737/01A AU 2273701 A AU2273701 A AU 2273701A AU 2273701 A AU2273701 A AU 2273701A
Authority
AU
Australia
Prior art keywords
associated antigen
hla class
tumor associated
vaccine compositions
antigen peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22737/01A
Inventor
Esteban Celis
Robert Chesnut
John Fikes
Elissa Keogh
Alessandro Sette
John Sidney
Scott Southwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/543,608 external-priority patent/US6602510B1/en
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of AU2273701A publication Critical patent/AU2273701A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU22737/01A 1999-12-13 2000-12-13 Hla class i a2 tumor associated antigen peptides and vaccine compositions Abandoned AU2273701A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US17044899P 1999-12-13 1999-12-13
US60170448 1999-12-13
US09543608 2000-04-05
US09/543,608 US6602510B1 (en) 2000-04-05 2000-04-05 HLA class I A2 tumor associated antigen peptides and vaccine compositions
US58320000A 2000-05-30 2000-05-30
US09583200 2000-05-30
PCT/US2000/034318 WO2001041741A1 (en) 1999-12-13 2000-12-13 Hla class i a2 tumor associated antigen peptides and vaccine compositions

Publications (1)

Publication Number Publication Date
AU2273701A true AU2273701A (en) 2001-06-18

Family

ID=27389823

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22737/01A Abandoned AU2273701A (en) 1999-12-13 2000-12-13 Hla class i a2 tumor associated antigen peptides and vaccine compositions

Country Status (5)

Country Link
EP (1) EP1242049A4 (en)
JP (1) JP2003516344A (en)
AU (1) AU2273701A (en)
CA (1) CA2393730A1 (en)
WO (1) WO2001041741A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020616A1 (en) * 2000-09-01 2002-03-14 Epimmune Inc. Hla-a2.1 binding peptides and their uses
AU2003296330A1 (en) * 2002-12-10 2004-06-30 Epimmune Inc. Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
EP1903056A3 (en) * 2002-12-10 2008-05-07 Idm Pharma, Inc. HLA-A1, -A2 -A3, -A24, -B7, and -B44 binding peptides comprising tumor associated antigen epitopes, and compositions thereof
AU2003285280A1 (en) * 2002-12-11 2004-06-30 Pharmexa A/S Targeting single epitopes
AU2004232971A1 (en) 2003-04-18 2004-11-04 Idm Pharma Inc. HLA-A2 tumor associated antigen peptides and compositions
JP5015601B2 (en) 2003-10-21 2012-08-29 セダーズ−シナイ メディカル センター Systems and methods for the treatment of cancer, including cancer of the central nervous system
US8129184B2 (en) 2006-09-26 2012-03-06 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039974A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
CN102066410B (en) * 2007-11-01 2017-01-18 梅约医学教育与研究基金会 HLA-DR binding peptides and application thereof
WO2010028066A2 (en) 2008-09-02 2010-03-11 Cedars-Sinai Medical Center Cd133 epitopes
US9249187B2 (en) 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof
WO2010115046A2 (en) * 2009-04-01 2010-10-07 University Of Miami Vaccine compositions and methods of use thereof
PT2427485T (en) 2009-05-07 2017-03-13 Immunocellular Therapeutics Ltd Cd133 epitopes
EP2762157A1 (en) * 2013-02-05 2014-08-06 Nitto Denko Corporation Vaccine composition for transdermal or mucosal administration
US10076491B2 (en) 2013-02-05 2018-09-18 Nitto Denko Corporation Vaccine composition
CA2898474A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
KR101851666B1 (en) 2013-03-08 2018-04-24 다이호야쿠힌고교 가부시키가이샤 Novel peptide having 5 linked ctl epitopes
US10272144B2 (en) 2013-07-31 2019-04-30 Bioventures, Llc Compositions for and methods of treating and preventing targeting tumor associated carbohydrate antigens
AU2014337643B2 (en) 2013-10-21 2017-07-13 Taiho Pharmaceutical Co., Ltd. Novel four-CTL epitope-joined peptide
GB201504502D0 (en) * 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
HRP20210698T1 (en) 2015-12-22 2021-09-17 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201522667D0 (en) * 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201604458D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
DE102016123893A1 (en) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T cell receptors with improved binding
SG10201913582XA (en) 2017-04-26 2020-02-27 Eureka Therapeutics Inc Constructs specifically recognizing glypican 3 and uses thereof
AU2018338441B2 (en) * 2017-09-25 2025-08-14 Memorial Sloan Kettering Cancer Center Tumor mutational load and checkpoint immunotherapy
WO2019191494A1 (en) 2018-03-28 2019-10-03 Epicentrx, Inc. Personalized cancer vaccines
WO2020004622A1 (en) 2018-06-29 2020-01-02 大鵬薬品工業株式会社 Antitumor agent and evaluation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020127A1 (en) * 1993-03-05 1994-09-15 Cytel Corporation Hla-a2.1 binding peptides and their uses
CA2278189A1 (en) * 1997-01-31 1998-08-06 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl

Also Published As

Publication number Publication date
EP1242049A1 (en) 2002-09-25
EP1242049A4 (en) 2005-01-05
JP2003516344A (en) 2003-05-13
WO2001041741A9 (en) 2002-05-30
WO2001041741A1 (en) 2001-06-14
CA2393730A1 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
AU2273701A (en) Hla class i a2 tumor associated antigen peptides and vaccine compositions
PL1620456T3 (en) Hla-a2 tumor associated antigen peptides and compositions
AU7912100A (en) Pharmaceutical composition comprising an antigen
LU91328I2 (en) Human papillomavirus vaccine Ätypes 6,11,16,18Ü (recombinant, adsorbed)
AU2001255196A1 (en) Compositions and methods for enhancing immunogenicity of antigens
SI1150712T1 (en) Human papilloma virus vaccine formulations
NL300415I1 (en) Vaccine against antigens from bacteria
AU2001252458A1 (en) Molecular antigen arrays and vaccines
AU2003256912A1 (en) Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
IL148247A (en) Vaccine composition and uses thereof
AU3328900A (en) Influenza virus hemagglutinin-binding peptides
AU2003262094A1 (en) Cancer antigen peptide preparation
AU2001255260A1 (en) Macroaggregated protein conjugates as oral genetic immunization delivery agents
AU2001271976A1 (en) Microspheres and adjuvants for dna vaccine delivery
AU2977500A (en) Advanced antigen presentation platform
AU2002243314A1 (en) Immunogenic cancer peptides and uses thereof
AU4776800A (en) Acetylcholinesterase-derived peptides and uses thereof
AU7308200A (en) Novel hev antigenic peptide and methods
HUP0202770A3 (en) Human papilloma virus vaccine
AUPQ233799A0 (en) Recombinant sub-unit vaccine
AU2913400A (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
AU3364000A (en) Antigen of erysipelothirx rhusiopathiae comprising an immuno-protective epitope
AUPQ257199A0 (en) Vaccine antigens of moraxella
AU4957800A (en) Vaccine against isa virus
AU5632500A (en) Cancer associated antigens and uses therefor

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase